```html

Zollinger‑Ellison‑type Gastrinoma: A Complete Patient Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder characterised by one or more gastrin‑producing neuroendocrine tumours (gastrinomas) that arise most often in the pancreas or duodenum. The excess gastrin stimulates the stomach to secrete large amounts of gastric acid, leading to severe peptic ulcer disease, diarrhea, and a host of other gastrointestinal problems.

Although the term “Zollinger‑Ellison‑type gastrinoma” can refer to sporadic gastrinomas that behave like those seen in classic ZES, the underlying pathophysiology is the same: hypergastrinemia → hyperacidic gastric environment.

Who it affects – The condition can appear at any age but most patients are diagnosed between 30 and 60 years. Men and women are affected equally (≈1:1 ratio). Approximately 20–25 % of gastrinomas are associated with the inherited condition multiple endocrine neoplasia type 1 (MEN‑1), while the remaining 75–80 % are sporadic.

Prevalence – Gastrinomas are the most common functional pancreatic neuroendocrine tumour, with an estimated incidence of 0.5–2 cases per million people per year (Mayo Clinic; NIH). Because many tumours are small and asymptomatic, the true prevalence may be slightly higher.

Symptoms

Symptoms result from two main mechanisms: (1) excess gastric acid causing ulcer disease, and (2) the tumour itself or its metastases. The following list includes the most frequently reported complaints, each with a brief description.

Gastro‑intestinal symptoms

• Recurrent or refractory peptic ulcers – Ulcers that do not heal with standard therapy, often located in unusual sites such as the jejunum or distal duodenum.
• Abdominal pain – Typically a burning or gnawing pain that improves after eating (due to neutralisation of acid) but may also worsen with meals.
• Diarrhea – Occurs in 50–70 % of patients; acidic contents inactivate pancreatic enzymes and damage the intestinal mucosa, leading to malabsorption.
• Steatorrhea (fatty stools) – Fat malabsorption secondary to pancreatic enzyme inactivation.
• Nausea and vomiting – Can be triggered by ulcer pain or by gastric outlet obstruction from ulcer scarring.
• Gastro‑esophageal reflux disease (GERD) – Excess acid may reflux into the esophagus, causing heartburn.

Systemic symptoms

• Weight loss – Due to malabsorption and chronic diarrhoea.
• Fatigue – Resulting from anaemia (ulcer‑related blood loss) or nutrient deficiencies.
• Secretory diarrhea leading to electrolyte disturbances – Low potassium and bicarbonate may cause muscle cramps or arrhythmias.

Symptoms related to tumour spread (metastasis)

• Abdominal mass or fullness – Large primary tumours can be palpable.
• Jaundice – If metastatic lesions compress the bile duct.
• Bone pain – Rarely, gastrinomas metastasise to bone.

Causes and Risk Factors

Gastrinomas arise from the neuroendocrine (NE) cells of the gastrointestinal tract. The exact trigger for sporadic tumours is unknown, but several factors have been identified.

Genetic factors

• MEN‑1 syndrome – Mutations in the MEN1 tumor suppressor gene predispose to gastrinomas as well as parathyroid, pituitary, and other pancreatic NETs. Up to 25 % of Zollinger‑Ellison cases occur in MEN‑1 patients (NIH).
• Familial isolated gastrinoma – Rare autosomal‑dominant inheritance without other MEN‑1 features.

Environmental / lifestyle factors

• There is no clear link to smoking, alcohol, or diet, unlike classic peptic ulcer disease.
• Chronic use of proton‑pump inhibitors (PPIs) does not cause gastrinomas, but long‑term PPI therapy can mask ulcer symptoms, delaying diagnosis.

Who is at higher risk?

• Individuals with known MEN‑1 mutation or a family history of gastrinoma.
• Patients previously diagnosed with a pancreatic neuroendocrine tumour (NET) of any type.
• Adults aged 30‑60 years (peak incidence).

Diagnosis

Because the disease can mimic common ulcer disorders, a high index of suspicion is required, especially in patients with ulcers that are multiple, refractory, or distal to the duodenum.

Laboratory Tests

• Fasting serum gastrin level – The cornerstone test. Levels > 1,000 pg/mL (10 × upper limit) are highly suggestive of gastrinoma, especially when the gastric pH is < 2. Reference: Mayo Clinic.
• Secretin stimulation test – In patients with borderline gastrin levels, an intravenous bolus of secretin paradoxically raises gastrin > 120 pg/mL in > 80 % of gastrinoma cases (NEJM, 2020).
• Gastric pH measurement – Low pH (< 2) supports acid hypersecretion.
• Chromogranin A (CgA) – A general neuroendocrine marker; elevated in > 70 % of gastrinomas but can be raised by PPIs or renal impairment.

Imaging Studies

• Multiphasic contrast‑enhanced CT scan – Detects primary tumours > 1 cm and evaluates liver metastases (sensitivity ≈ 70‑80 %).
• Magnetic Resonance Imaging (MRI) with diffusion‑weighted sequences – Improves detection of small liver lesions and pancreatic tail tumours.
• Endoscopic ultrasound (EUS) – Highly sensitive (≈ 90 %) for tumours ≤ 2 cm and allows fine‑needle aspiration for histology.
• Somatostatin receptor scintigraphy (Octreoscan) or Gallium‑68 DOTATATE PET/CT – Gold standard for staging; detects most gastrinomas because they over‑express somatostatin receptors.

Histopathology

If tissue is obtained, the tumour shows uniform nests of neuroendocrine cells positive for gastrin, chromogranin A, and synaptophysin. The Ki‑67 proliferation index helps grade the tumour (WHO 2017 classification).

Diagnostic Criteria Summary

1. Fasting gastrin > 1,000 pg/mL or positive secretin stimulation test.
2. Documented gastric acid hypersecretion (pH < 2).
3. Imaging that localises a gastrinoma (pancreas, duodenum, or lymph node).

Treatment Options

Management aims to control acid hypersecretion, remove or reduce tumour burden, and monitor for recurrence.

Medical Therapy – Controlling Acid

• Proton‑pump inhibitors (PPIs) – High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses often exceed standard ulcer doses (e.g., omeprazole 60–80 mg daily). PPIs effectively heal ulcers and relieve diarrhoea.
• Histamine‑2 receptor antagonists (H2RAs) – May be added as adjuncts, but PPIs are superior for ZES.
• Somatostatin analogues (Octreotide, Lanreotide) – Bind somatostatin receptors on gastrinoma cells, reducing gastrin secretion and, in some cases, tumour size. Particularly useful in patients with uncontrolled symptoms despite maximal PPIs.

Surgical Management

• Curative resection – Indicated for non‑metastatic tumours or when the primary can be fully excised (e.g., duodenal gastrinoma with negative margins). En‑bloc pancreaticoduodenectomy (Whipple) or limited duodenal resection may be performed.
• Enucleation – For small (< 2 cm), well‑circumscribed lesions not involving major ducts.
• Debulking surgery – In metastatic disease, removal of > 90 % of tumour bulk can improve symptom control and prolong survival.

Targeted & Systemic Therapies (for metastatic or unresectable disease)

• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; response rates ≈ 60 % (Lancet Oncology, 2021).
• Everolimus – An mTOR inhibitor shown to prolong progression‑free survival in pancreatic NETs (RADIANT‑3 trial).
• Sunitinib – A tyrosine‑kinase inhibitor with activity against NETs.
• Chemotherapy – Typically reserved for high‑grade (Ki‑67 > 20 %) neuroendocrine carcinomas; regimens include streptozocin‑based combos.

Liver‑directed therapies

• Radiofrequency ablation (RFA) or microwave ablation for limited hepatic metastases.
• Trans‑arterial chemo‑embolisation (TACE) for bulky liver disease.

Lifestyle & Supportive Measures

• Maintain a diet low in fatty foods to minimise steatorrhea.
• Stay hydrated; oral rehydration solutions help replace lost electrolytes.
• Regular vitamin B12, iron, and fat‑soluble vitamin (A, D, E, K) supplementation if malabsorption persists.

Living with Zollinger‑Ellison‑type Gastrinoma

Long‑term management is a partnership between you, your gastroenterologist, endocrinologist, and surgeon. Below are practical tips to help you stay healthy.

Medication Adherence

• Take PPIs exactly as prescribed; missing a dose can precipitate breakthrough ulcer pain.
• Set a daily alarm for somatostatin analogue injections or arrange a home‑nurse visit.
• Inform any new prescriber that you are on high‑dose PPI therapy to avoid drug interactions.

Nutrition

• Eat small, frequent meals – this reduces gastric acid spikes.
• Choose lean proteins, cooked vegetables, and low‑fat grains.
• Avoid caffeine, alcohol, and spicy foods which can exacerbate acid secretion.
• If you develop persistent diarrhoea, a dietitian can help you implement a low‑FODMAP or medium‑chain triglyceride (MCT) regimen.

Monitoring & Follow‑up

• Serum gastrin and CgA levels every 6‑12 months (or sooner if symptoms change).
• Annual imaging (MRI or Gallium‑68 DOTATATE PET/CT) to detect recurrence or new metastases.
• Bone density testing every 2‑3 years if you are on long‑term somatostatin analogues, as they can affect calcium metabolism.

Psychosocial Support

• Join patient support groups (e.g., NET Patient Foundation) – sharing experiences reduces anxiety.
• Consider counselling if chronic pain or frequent hospital visits impact mental health.

Prevention

Because most gastrinomas are sporadic and linked to genetic mutations, primary prevention is limited. However, you can take steps that may lower overall risk and improve outcomes.

• Genetic counseling – If you have a family history of MEN‑1 or gastrinoma, undergo testing. Early detection allows surveillance before tumours become symptomatic.
• Routine medical care – Prompt evaluation of atypical or refractory ulcers can lead to earlier diagnosis.
• Avoid unnecessary prolonged PPI use – Use the lowest effective dose and discuss step‑down plans with your doctor after disease control.

Complications

If left untreated or inadequately controlled, gastrinomas can cause serious health problems.

• Recurrent or perforated peptic ulcers – Can lead to abdominal sepsis, peritonitis, or bleeding requiring emergency surgery.
• Gastro‑intestinal bleeding – Chronic ulceration may cause chronic iron‑deficiency anaemia.
• Severe diarrhoea and electrolyte imbalance – Hypokalaemia, metabolic alkalosis, and dehydration can provoke cardiac arrhythmias.
• Malnutrition and weight loss – Chronic malabsorption may lead to cachexia.
• Metastatic disease – Liver is the most common site; liver failure can occur.
• Secondary osteoporosis – Chronic acid hypersecretion impairs calcium absorption.
• Reduced quality of life – Persistent pain, fear of ulcer complications, and frequent medication adjustments.

When to Seek Emergency Care

Early medical attention can be lifesaving. Keep this information handy and share it with family members.

---

Sources: Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cancer Institute (NCI), American Cancer Society, World Health Organization (WHO), Cleveland Clinic, New England Journal of Medicine, Lancet Oncology, National Comprehensive Cancer Network (NCCN) guidelines, and peer‑reviewed articles up to 2024.

```